Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Woodall

Surgical Oncology Springfield, MO Medical Doctor

NPI 1730279506 CMS profile 124377

1001 E Primrose St, Springfield, MO 65807

Open in the dashboard

General payments

$6,896

60 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Woodall of Springfield, MO is reported in the CMS Open Payments database as having received $6,896 across 60 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Surgical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $184 8
2024 General $47 2
2023 General $72 4
2022 General $98 5
2021 General $91 6
2020 General $144 10
2019 General $6,259 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Woodall
  • Surgical Oncology median
  • Middle half of Surgical Oncology
  • National median

In program year 2025, general payments to Charles Woodall were reported at $184. Among 1,137 Surgical Oncology profiles paid that year, the median was $288 and the middle half received between $118 and $1,346.

Show as a table
Year Charles Woodall Surgical Oncology median Middle half National median
2019 $6,259 $236 $86–$1,064 $163
2020 $144 $130 $47–$648 $114
2021 $91 $160 $53–$943 $132
2022 $98 $199 $76–$782 $149
2023 $72 $246 $95–$854 $160
2024 $47 $271 $106–$1,123 $164
2025 $184 $288 $118–$1,346 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sirtex Medical Inc $6,078 14 payments
  2. AbbVie, Inc. $479 29 payments
  3. Boston Scientific Corporation $85 4 payments
  4. Allergan Inc. $52 3 payments
  5. TELA Bio, Inc. $42 1 payment
  6. Novartis Pharmaceuticals Corporation $41 2 payments
  7. Advanced Accelerator Applications $28 2 payments
  8. Covidien LP $24 1 payment
  9. Vertex Pharmaceuticals Incorporated $21 1 payment
  10. CONMED Corporation $18 1 payment
  11. Other $28 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $4,500 1 payment
  2. Travel and Lodging $1,377 7 payments
  3. Food and Beverage $1,019 52 payments
Products named General payments · program years 2019–2025
  1. SIR-Spheres Microspheres $6,078 14 payments
  2. CREON $460 28 payments
  3. LUTATHERA $69 4 payments
  4. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $42 1 payment
  5. STRATTICE $33 2 payments
  6. EXALT Model D $29 1 payment
  7. WALLFLEX $24 1 payment
  8. Bravo $24 1 payment
  9. JOURNAVX $21 1 payment
  10. STRATTICE LAP $18 1 payment
  11. Other $78 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

345

Median for Surgical Oncology: 44

Drug cost

$42,786

Median for Surgical Oncology: $327

Branded share of claims

51.9%

Median for Surgical Oncology: 14.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 14 $39,439
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 165 $1,027
Sucralfate Generic 31 $977
Oxycodone Hcl Generic 49 $866
Omeprazole Generic 33 $273
Pantoprazole Sodium Generic 22 $112
Ciprofloxacin Hcl Generic 14 $63
Tramadol Hcl Generic 17 $29

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 682 Part D prescribers listed as Surgical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 151 billing codes

Paid by Medicare

$198,415

Medicare's payments for the services billed

Medicare patients

375

Average age 73

Services billed

1,656

174 women, 201 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 33%
Ischemic heart disease 30%
Chronic kidney disease 30%
Atrial fibrillation 27%
Cancer 27%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

60 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgical Oncology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record